{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:59:21Z","timestamp":1791190761709,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":106,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ajpath.2012.12.028","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T05:03:52Z","timestamp":1360299832000},"page":"1065-1077","source":"Crossref","is-referenced-by-count":92,"title":["New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas"],"prefix":"10.1016","volume":"182","author":[{"given":"Brooke T.","family":"Mossman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas H.","family":"Heintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire F.","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ajpath.2012.12.028_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10408440802273156","article-title":"A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type","volume":"38","author":"Berman","year":"2008","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/oem.57.8.563","article-title":"Risk of mesothelioma from exposure to crocidolite asbestos: a 1995 update of a South African mortality study","volume":"57","author":"Kielkowski","year":"2000","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1126\/science.7350661","article-title":"Asbestos-induced epithelial changes in organ cultures of hamster trachea: inhibition by retinyl methyl ether","volume":"207","author":"Mossman","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2012.12.028_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/10937404.2011.556047","article-title":"Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos","volume":"14","author":"Mossman","year":"2011","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.ajpath.2012.12.028_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2214\/ajr.161.3.8394641","article-title":"Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: cT findings in 84 patients","volume":"161","author":"Sahin","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MCP.0b013e32834e897d","article-title":"Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases","volume":"18","author":"Antao","year":"2012","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5858\/arpa.2011-0039-RA","article-title":"Mesothelioma not associated with asbestos exposure","volume":"136","author":"Jasani","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"Suppl 4","key":"10.1016\/j.ajpath.2012.12.028_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdp134","article-title":"Malignant pleural mesothelioma: eSMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Stahel","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib9","first-page":"472","article-title":"Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features","volume":"5","author":"Taskin","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib11","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib12","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCP.0b013e32812144bb","article-title":"Biomarkers for mesothelioma","volume":"13","author":"Scherpereel","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib14","doi-asserted-by":"crossref","first-page":"e25391","DOI":"10.1371\/journal.pone.0025391","article-title":"LRRN4 and UPK3B are markers of primary mesothelial cells","volume":"6","author":"Kanamori-Katayama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2012.12.028_bib15","first-page":"1","article-title":"Structure and function of mesothelial cells","volume":"134","author":"Mutsaers","year":"2007","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/039139880703000611","article-title":"The potential of mesothelial cells in tissue engineering and regenerative medicine applications","volume":"30","author":"Herrick","year":"2007","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.ajpath.2012.12.028_bib17","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1073\/pnas.0808649105","article-title":"Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development","volume":"105","author":"Que","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2012.12.028_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.24119","article-title":"Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver","volume":"53","author":"Asahina","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2012.12.028_bib19","first-page":"437","article-title":"Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed","volume":"37","author":"Cortes-Dericks","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1743-8977-7-5","article-title":"Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma","volume":"7","author":"Donaldson","year":"2010","journal-title":"Part Fibre Toxicol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1383-5718(00)00043-7","article-title":"Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos","volume":"468","author":"Ni","year":"2000","journal-title":"Mutat Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1349-7006.1995.tb03308.x","article-title":"Low incidence of point mutations in H-. K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate","volume":"86","author":"Nishiyama","year":"1995","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib23","first-page":"425","article-title":"Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas","volume":"18","author":"Papp","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","article-title":"Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways","volume":"42","author":"Heintz","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib25","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2012.12.028_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ajpath.2012.12.028_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.mrgentox.2011.04.008","article-title":"Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells","volume":"723","author":"Wang","year":"2011","journal-title":"Mutat Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Shukla","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-04-0243","article-title":"Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase\/AKT activity that predict the efficacy of Onconase","volume":"4","author":"Ramos-Nino","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2012.12.028_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajpath.2012.12.028_bib31","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2012.12.028_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","article-title":"Nf2\/Merlin: a coordinator of receptor signalling and intercellular contact","volume":"98","author":"Curto","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib33","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","article-title":"The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression","volume":"25","author":"Xiao","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib34","doi-asserted-by":"crossref","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2012.12.028_bib35","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib36","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yexmp.2012.04.001","article-title":"Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients","volume":"93","author":"Bahnassy","year":"2012","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib38","first-page":"2085","article-title":"Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-L-cysteine in mesothelial cells","volume":"55","author":"Janssen","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib39","doi-asserted-by":"crossref","first-page":"L1018","DOI":"10.1152\/ajplung.00038.2003","article-title":"Asbestos induces mitochondrial DNA damage and dysfunction linked to the development of apoptosis","volume":"285","author":"Shukla","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1165\/ajrcmb.17.3.2991","article-title":"Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos","volume":"17","author":"Goldberg","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib41","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib42","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers","volume":"152","author":"Pache","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib43","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1038\/sj.onc.1207195","article-title":"\u03921-integrin mediates asbestos-induced phosphorylation of AKT and ERK1\/2 in a rat pleural mesothelial cell line","volume":"22","author":"Berken","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2012.12.028_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1165\/rcmb.2007-0460OC","article-title":"mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids","volume":"39","author":"Wilson","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib45","first-page":"6065","article-title":"Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression","volume":"62","author":"Ramos-Nino","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajpath.2012.12.028_bib47","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1158\/0008-5472.CAN-04-0946","article-title":"The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos","volume":"64","author":"Yuan","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1476-4598-9-314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Shukla","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib49","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1538-7445.AM2012-5461","article-title":"Role of the NLRP3 inflammasome in the development and drug resistance of malignant mesothelioma","volume":"72","author":"Shukla","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib50","doi-asserted-by":"crossref","first-page":"e39404","DOI":"10.1371\/journal.pone.0039404","article-title":"Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells","volume":"7","author":"Newick","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2012.12.028_bib51","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/MCG.0b013e31824e901b","article-title":"Serum thioredoxin-1 as a diagnostic marker for malignant peritoneal mesothelioma","volume":"47","author":"Tabata","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib52","doi-asserted-by":"crossref","first-page":"25369","DOI":"10.1074\/jbc.M414498200","article-title":"Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress","volume":"280","author":"Stapelberg","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.12.028_bib53","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10937404.2011.556052","article-title":"Factors that impact susceptibility to fiber-induced health effects","volume":"14","author":"Below","year":"2011","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.ajpath.2012.12.028_bib54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2012.12.028_bib55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10937404.2011.556051","article-title":"Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases","volume":"14","author":"Huang","year":"2011","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.ajpath.2012.12.028_bib56","first-page":"189","article-title":"Asbestos increases mammalian AP-endonuclease gene expression, protein levels, and\u00a0enzyme activity in mesothelial cells","volume":"58","author":"Fung","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1165\/ajrcmb.23.3.4094","article-title":"Phagocytosis of crocidolite asbestos induces oxidative stress. DNA damage, and apoptosis in mesothelial cells","volume":"23","author":"Liu","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib58","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1289\/ehp.1002312","article-title":"XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and Libby amphibole","volume":"118","author":"Pietruska","year":"2010","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.ajpath.2012.12.028_bib59","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c\u2217 is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000334237","article-title":"miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment","volume":"81","author":"Ghawanmeh","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.ajpath.2012.12.028_bib61","first-page":"426","article-title":"Acute injury and regeneration of the mesothelium in response to asbestos fibers","volume":"128","author":"Moalli","year":"1987","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib62","first-page":"271","article-title":"Inflammation generating potential of long and short fibre amosite asbestos samples","volume":"46","author":"Donaldson","year":"1989","journal-title":"Br J Ind Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib63","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1183\/09031936.97.10010219","article-title":"Physiology and pathophysiology of pleural fluid turnover","volume":"10","author":"Miserocchi","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajpath.2012.12.028_bib64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2008-0146OC","article-title":"Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity","volume":"41","author":"Shukla","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/15287390903486568","article-title":"Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9\/TERT-1)","volume":"73","author":"Hillegass","year":"2010","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.ajpath.2012.12.028_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","article-title":"Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model","volume":"1203","author":"Hillegass","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajpath.2012.12.028_bib67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2012.12.028_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1476-4598-8-91","article-title":"Mechanisms of FUS1\/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects","volume":"8","author":"Ivanova","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib69","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib71","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.it.2011.12.001","article-title":"Differential macrophage programming in the tumor microenvironment","volume":"33","author":"Ruffell","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib73","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.ajpath.2012.12.028_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.6004\/jnccn.2012.0006","article-title":"Malignant pleural mesothelioma. Clinical practice guidelines in oncology","volume":"10","author":"Ettinger","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ajpath.2012.12.028_bib75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/labinvest.2008.15","article-title":"Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium","volume":"88","author":"Ito","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.ajpath.2012.12.028_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity: N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1476-4598-6-81","article-title":"Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas","volume":"6","author":"Ramos-Nino","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ajpath.2012.12.028_bib80","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1097\/JTO.0b013e3181ed0489","article-title":"A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"5","author":"Cao","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11864-011-0154-4","article-title":"Surgical treatment of malignant pleural mesothelioma","volume":"12","author":"Kaufman","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib82","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib83","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/JTO.0b013e3182208e3f","volume":"6","author":"Rice","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(00)00192-6","article-title":"Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients","volume":"31","author":"Castagneto","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jtcvs.2009.02.046","article-title":"Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study","volume":"138","author":"Tilleman","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ajpath.2012.12.028_bib86","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/BF02303746","article-title":"Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma","volume":"4","author":"Pass","year":"1997","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib88","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ajpath.2012.12.028_bib89","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.freeradbiomed.2006.04.031","article-title":"Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress","volume":"41","author":"Nilsonne","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib90","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0360-3016(98)00409-X","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single-institution experience with 189 patients","volume":"43","author":"de Graaf-Strukowska","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajpath.2012.12.028_bib91","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/JTO.0b013e3182199819","article-title":"Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma","volume":"6","author":"Chi","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib92","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ajpath.2012.12.028_bib93","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib94","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib95","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/13543784.2012.681641","article-title":"Anti-angiogenic therapies for malignant pleural mesothelioma","volume":"21","author":"Ceresoli","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ajpath.2012.12.028_bib96","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib97","doi-asserted-by":"crossref","first-page":"42","DOI":"10.6004\/jnccn.2012.0007","article-title":"Novel therapies in phase II and III trials for malignant pleural mesothelioma","volume":"10","author":"Zauderer","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ajpath.2012.12.028_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JTO.0b013e3181c5e366","article-title":"Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials","volume":"5","author":"Paik","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma: a phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajpath.2012.12.028_bib101","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0959-8049(11)70098-3","article-title":"VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial","volume":"47","author":"Krug","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib104","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib105","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib106","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ajpath.2012.12.028_bib107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ajpath.2012.12.028_bib108","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib109","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ajpath.2012.12.028_bib110","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib111","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/1078-0432.CCR-10-2345","article-title":"Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors","volume":"17","author":"Shapiro","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib112","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ajpath.2012.12.028_bib113","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2403817","article-title":"Wilms\u2019 tumour gene 1 (WT1) in human neoplasia","volume":"19","author":"Keilholz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ajpath.2012.12.028_bib114","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ajpath.2012.12.028_bib115","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib116","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib117","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib118","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","article-title":"Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.7026","article-title":"Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response","volume":"29","author":"Hassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2012.12.028_bib120","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-11-0493","article-title":"Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts","volume":"17","author":"Mossoba","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib121","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib122","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1158\/1078-0432.CCR-11-1235","article-title":"Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody","volume":"17","author":"Du","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.12.028_bib123","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","article-title":"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks","volume":"149","author":"Lee","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2012.12.028_bib124","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ajpath.2012.12.028_bib125","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1158\/1078-0432.CCR-11-2375","article-title":"New strategies in pleural mesothelioma: bAP1 and NF2 as novel targets for therapeutic development and risk assessment","volume":"18","author":"Ladanyi","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944013000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944013000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T02:13:56Z","timestamp":1595384036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944013000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0002944013000382"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.12.028","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}